Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-11-06

FDA Approved: AMBRISENTAN — Supplemental Application (Sun Pharmaceutical Industries, Inc.)

View source ↗

Summary

FDA approved Sun Pharmaceutical Industries' supplemental application for AMBRISENTAN (ambrisentan), authorizing the generic version's approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ambrisentan (Ambrisentan)

Snippet

SUPPL AP for AMBRISENTAN (AMBRISENTAN)